Another Good Program Bites The Dust

Legal Insurrection is reporting today that the Biden administration is taking steps to remove the Trump administration policy put in place to lower the cost of insulin and epi-pens.

The article reports:

Biden’s bid to retract the rule was approved on Monday, as reported by Politico, with the expectation that the Department of Health and Human Services could publish the retraction within the coming days.

The measure, signed off on under the previous administration in December, aimed to require some 340B community health centers to deliver savings to low-income patients for insulin and epinephrine in a bid to bring down unaffordable prices.

Spokespeople for the White House and the Department of Health and Human Services did not return FOX Business’ request for comment.

The article notes:

Just after Biden was Inaugurated, USA Today “fact checked” the claim that such a move was planned. Once again, the press is forced to do a fact-reversal, one in a long stream of many we have covered at Legal Insurrection.

For diabetic patients, out-of-pocket costs for insulin can be a major expense, whether they are insured in the commercial market, enrolled in Medicare, or have no insurance. The savings Trump created was substantial.

The current group of fact-checkers have a rather questionable track record. It should be noted that most of the things ‘fact-checked’ are things that might portray President Trump in a good light or President Biden in a bad light.

The article concludes:

The Biden administration said Friday it has no timeline on whether it will allow states to import drugs from Canada, an effort that was approved under President Donald Trump as a key strategy to control costs.

Six states have passed laws to start such programs, and Florida, Colorado and New Mexico are the furthest along in plans to get federal approval.

The Biden administration said states still have several hurdles to get through, including a review by the Food and Drug Administration, and such efforts may face pressures from the Canadian government, which has warned its drug industry not to do anything that could cause drug shortages in that country.

“Although two proposals have been submitted to FDA, no timeline exists for the agency to make a decision. Thus, the possible future injuries to Plaintiffs’ members are overly speculative and not imminent,” the Biden administration wrote in a court filing late Friday seeking to dismiss a lawsuit from the Pharmaceutical Research and Manufacturers of America, an industry trade group. Drugmakers are asking the court to overturn the rule set by the Health and Human Services Department in October that for the first time approved allowing states to import drugs from Canada.

The Biden presidency is proving to be very costly and painful for average Americans.

The information in this article is also found at Fox News and Politico.